Investment analysts at Deutsche Bank started coverage on shares of Diplomat Pharmacy (NYSE:DPLO) in a research note issued on Monday, MarketBeat.com reports. The firm set a “buy” rating and a $22.00 price target on the stock. Deutsche Bank’s price objective suggests a potential upside of 20.81% from the stock’s previous close.

Several other equities analysts also recently commented on DPLO. Zacks Investment Research upgraded Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. TheStreet upgraded Diplomat Pharmacy from a “d+” rating to a “c-” rating in a research report on Thursday, August 10th. BidaskClub upgraded Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research report on Friday, September 15th. Robert W. Baird restated a “buy” rating and set a $20.00 price objective on shares of Diplomat Pharmacy in a research report on Sunday, September 17th. Finally, Needham & Company LLC restated a “buy” rating and set a $23.75 price objective (up from $19.75) on shares of Diplomat Pharmacy in a research report on Wednesday, October 4th. Six research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $20.39.

Diplomat Pharmacy (NYSE DPLO) traded up $0.48 during trading on Monday, reaching $18.21. The company’s stock had a trading volume of 949,968 shares, compared to its average volume of 812,209. The company has a quick ratio of 0.82, a current ratio of 1.34 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $1,221.12, a P/E ratio of 23.03, a PEG ratio of 3.19 and a beta of 0.61. Diplomat Pharmacy has a 1 year low of $12.25 and a 1 year high of $21.99.

Diplomat Pharmacy (NYSE:DPLO) last posted its earnings results on Monday, November 6th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.15 by $0.10. The firm had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.16 billion. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The business’s quarterly revenue was down 4.8% on a year-over-year basis. During the same period last year, the company earned $0.21 earnings per share. equities research analysts forecast that Diplomat Pharmacy will post 0.85 EPS for the current year.

In other news, Director Jeffrey G. Park acquired 3,000 shares of Diplomat Pharmacy stock in a transaction on Monday, November 20th. The stock was purchased at an average price of $15.46 per share, with a total value of $46,380.00. Following the completion of the purchase, the director now owns 7,640 shares of the company’s stock, valued at approximately $118,114.40. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Atul Kavthekar acquired 2,000 shares of Diplomat Pharmacy stock in a transaction on Monday, November 20th. The stock was purchased at an average cost of $15.00 per share, with a total value of $30,000.00. Following the purchase, the chief financial officer now directly owns 2,000 shares of the company’s stock, valued at approximately $30,000. The disclosure for this purchase can be found here. Insiders have purchased 15,000 shares of company stock valued at $228,780 in the last ninety days. 30.20% of the stock is currently owned by insiders.

A number of institutional investors have recently made changes to their positions in the business. Royal Bank of Canada lifted its holdings in shares of Diplomat Pharmacy by 25.0% in the second quarter. Royal Bank of Canada now owns 35,266 shares of the company’s stock valued at $521,000 after purchasing an additional 7,056 shares in the last quarter. State of Wisconsin Investment Board lifted its holdings in shares of Diplomat Pharmacy by 9.9% in the second quarter. State of Wisconsin Investment Board now owns 278,000 shares of the company’s stock valued at $4,114,000 after purchasing an additional 25,000 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Diplomat Pharmacy by 19.3% in the second quarter. Ameriprise Financial Inc. now owns 272,979 shares of the company’s stock valued at $4,043,000 after purchasing an additional 44,135 shares in the last quarter. Crossmark Global Holdings Inc. bought a new position in shares of Diplomat Pharmacy in the third quarter valued at approximately $538,000. Finally, Parametric Portfolio Associates LLC lifted its holdings in shares of Diplomat Pharmacy by 54.8% in the second quarter. Parametric Portfolio Associates LLC now owns 86,544 shares of the company’s stock valued at $1,281,000 after purchasing an additional 30,645 shares in the last quarter. 72.48% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Deutsche Bank Initiates Coverage on Diplomat Pharmacy (DPLO)” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/12/04/deutsche-bank-initiates-coverage-on-diplomat-pharmacy-dplo.html.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.